In Vitro Activity of Novel Antifungal Olorofim against Filamentous Fungi and Comparison to Eight Other Antifungal Agents.
Aspergillus fumigatus
F901318
Fusarium spp.
antifungal agents
dark molds
filamentous fungi
multidrug resistance
olorofim
Journal
Journal of fungi (Basel, Switzerland)
ISSN: 2309-608X
Titre abrégé: J Fungi (Basel)
Pays: Switzerland
ID NLM: 101671827
Informations de publication
Date de publication:
12 May 2021
12 May 2021
Historique:
received:
07
04
2021
revised:
03
05
2021
accepted:
08
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Olorofim is a novel antifungal drug that belongs to the orotomide drug class which inhibits fungal dihydroorotate dehydrogenase (DHODH), thus halting pyrimidine biosynthesis and ultimately DNA synthesis, cell growth and division. It is being developed at a time when many invasive fungal infections exhibit antifungal resistance or have limited treatment options. The goal of this study was to evaluate the in vitro effectiveness of olorofim against a large collection of recently isolated, clinically relevant American mold isolates. In vitro antifungal activity was determined for 246 azole-susceptible
Identifiants
pubmed: 34065811
pii: jof7050378
doi: 10.3390/jof7050378
pmc: PMC8150786
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Antimicrob Agents Chemother. 2018 Jul 27;62(8):
pubmed: 29784842
J Antimicrob Chemother. 2020 Apr 1;75(4):936-941
pubmed: 31904836
N Engl J Med. 2007 Apr 5;356(14):1481-3
pubmed: 17409336
Antimicrob Agents Chemother. 2018 Aug 27;62(9):
pubmed: 29941638
J Antimicrob Chemother. 2017 Sep 1;72(9):2548-2552
pubmed: 28605488
J Clin Microbiol. 2016 Sep;54(9):2288-93
pubmed: 27335151
J Antimicrob Chemother. 2019 Jun 1;74(6):1586-1590
pubmed: 30891600
Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):12809-12814
pubmed: 27791100
Clin Pharmacol Drug Dev. 2017 Jan;6(1):44-53
pubmed: 27273461
PLoS Pathog. 2013 Oct;9(10):e1003633
pubmed: 24204249
Antimicrob Agents Chemother. 2018 Jul 27;62(8):
pubmed: 29891595
Infect Drug Resist. 2017 Aug 29;10:249-259
pubmed: 28919789
Infect Dis Clin North Am. 2016 Mar;30(1):1-11
pubmed: 26739604
Antimicrob Agents Chemother. 2018 Apr 26;62(5):
pubmed: 29463545
Clin Infect Dis. 2016 Feb 1;62(3):362-8
pubmed: 26486705
Open Forum Infect Dis. 2020 Jan 12;7(2):ofaa016
pubmed: 32099843
Clin Microbiol Infect. 2016 Jun;22(6):571.e1-4
pubmed: 26851656
Clin Microbiol Infect. 2019 Jun;25(6):681-687
pubmed: 30268672
Clin Microbiol Infect. 2019 Jul;25(7):799-806
pubmed: 30580035
Methods Mol Biol. 2017;1508:17-65
pubmed: 27837497
Sci Transl Med. 2012 Dec 19;4(165):165rv13
pubmed: 23253612
Crit Rev Microbiol. 2013 Aug;39(3):310-24
pubmed: 22917084
Antimicrob Agents Chemother. 2019 May 24;63(6):
pubmed: 30885903
J Antimicrob Chemother. 2018 Nov 1;73(11):3068-3073
pubmed: 30351438
Med Mycol. 2018 Apr 1;56(suppl_1):83-92
pubmed: 29538741
J Antimicrob Chemother. 2017 Sep 1;72(9):2443-2446
pubmed: 28575384
Antimicrob Agents Chemother. 2019 Oct 22;63(11):
pubmed: 31451501
Medicine (Baltimore). 2010 Jul;89(4):236-244
pubmed: 20616663
Thorax. 2015 Mar;70(3):270-7
pubmed: 25354514
Lancet Infect Dis. 2017 Dec;17(12):e383-e392
pubmed: 28774698
Med Mycol. 2018 Apr 1;56(suppl_1):93-101
pubmed: 29538730
Int J Antimicrob Agents. 2017 Nov;50(5):617-621
pubmed: 28802855
Lancet Infect Dis. 2016 Jul;16(7):828-837
pubmed: 26969258
Med Mycol. 2018 Nov 1;56(8):1050-1054
pubmed: 29370408